|
| SCC | AC | SCLC | ||||
| Feature | Strata | 1_3A (n = 9) | 3B_4 (n = 97) | 1_3A (n = 34) | 3B_4 (n = 417) | 1_3A (n = 9) | 3B_4 (n = 111) |
| Treatment | Adjuvant chemotherapy | 1 (11.11%) | 1 (1.03%) | 2 (5.88%) | 1 (0.24%) | 2 (22.22%) |
|
|
| Chemo + Radiotherapy |
|
| 1 (2.94%) | 3 (0.72%) |
| 4 (3.60%) |
|
| Concurrent chemo-radiotherapy |
| 3 (3.09%) | 9 (26.47%) | 3 (0.72%) | 4 (44.44%) | 5 (4.50%) |
|
| Definitive Radiotherapy | 2 (22.22%) |
| 5 (14.71%) | 11 (2.64%) |
| 3 (2.70%) |
|
| Neoadjuvant Chemo + Radiation |
|
|
|
| 1 (11.11%) |
|
|
| Neoadjuvant chemotherapy | 4 (44.44%) | 9 (9.28%) | 5 (14.71%) | 18 (4.32%) |
|
|
|
| Palliative Chemo + Radiation |
| 21 (21.65%) | 1 (2.94%) | 88 (21.10%) |
| 30 (27.03%) |
|
| Palliative chemotherapy | 2 (22.22%) | 36 (37.11%) | 4 (11.76%) | 168 (40.29%) |
| 43 (38.74%) |
|
| Palliative radiotherapy |
| 19 (19.59%) |
| 71 (17.03%) |
| 13 (11.71%) |
|
| Supportive care |
| 5 (5.15%) | 1 (2.94%) | 37 (8.87%) |
| 11 (9.91%) |
|
| Surgery |
|
| 1 (2.94%) | 7 (1.68%) |
|
|
| Sex-wise staging of cancer | Female | 2 (22.22%) | 13 (13.40%) | 10 (29.41%) | 121 (29.02%) | 1 (11.11%) | 20 (18.02%) |
|
| Male | 7 (77.78%) | 84 (86.60%) | 24 (70.59%) | 295 (70.74%) | 8 (88.89%) | 91 (81.98%) |